In accordance with the European Association for Nuclear Medicine guidelines pertaining to the pilot Phase II trial of [177Lu]Lu-PSMA-617, in [68Ga]Ga-PSMA-11 PET/CT, the SUVmax of the tumor lesion must be at least 1.5 times higher than the liver baseline SUVmean to qualify for treatment (83, 90). The gene discussed is FOLH1; the disease is neoplasm.